UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~April 279, 2025

89bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39122

36-4946844

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

655 Montgomery Street, Suite 1500

San Francisco, CA 94111

(Address of principal executive offices, including zip code)

(415) 432-9270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ETNB		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 27.0201 ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On ~~February 27~~April 9, 2025, ~~89bio, Inc. (~~the “Company”) ~~issued~~made aavailable ~~press~~an ~~release~~updated ~~announcing~~corporate ~~its~~presentation ~~financial~~on ~~results for~~ the ~~quarter~~Company’s ~~and year ended December 31, 2024~~website. ~~A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.~~

~~This~~A ~~Item~~copy ~~2.02~~of ~~and~~ the ~~Press~~corporate ~~Release~~presentation ~~attached~~is ~~hereto~~furnished as Exhibit 99.1, ~~insofar~~to asthis ~~they~~Current ~~disclose~~Report ~~information~~on ~~regarding~~Form ~~the~~8-K ~~Company’s~~and ~~results~~is incorporated by reference herein. The exhibit furnished under Item 7.01 of ~~operations~~this ~~and~~Current ~~financial~~Report ~~condition~~on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the ~~quarter~~Securities ~~and~~Exchange ~~year~~Act ~~ended~~of ~~December 31~~1934, ~~2024~~as amended (the “Exchange Act”), ~~are~~or ~~being~~otherwise ~~furnished~~subject to the ~~Securities~~liabilities ~~and~~of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange ~~Commission~~Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. ~~The following exhibits are being furnished herewith:~~

EXHIBIT INDEX

Exhibit No.		Description
99.1		~~Press~~Corporate ~~Release~~Presentation, dated ~~February~~April ~~27,~~ 2025
104		Cover ~~Page~~page ~~Interactive~~interactive ~~Data~~data ~~File~~file (embedded within the ~~Inline~~inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 27, 2025

/s/ Rohan Palekar

Date: April 9, 2025

/s/ Rohan Palekar

Rohan Palekar

Chief Executive Officer

Filing Compare · 89bio, Inc.